TKTL1 Enzyme Detection for Mammalian Glucose Fermentation Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and control mechanisms for the mammalian aerobic glucose fermentation metabolic pathway (mam-aGF), which is crucial for understanding and managing various diseases, including cancer and neurodegenerative disorders, due to the lack of specific markers and therapeutic targets.
Innovation Solution
The method involves using the TKTL1 enzyme as an indicator and target molecule for qualitative and quantitative detection of mam-aGF in biological samples, employing monoclonal antibodies and nucleic acid probes to assess its activity, concentration, localization, and dimerization status, and administering inhibitors or activators to modulate its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for mammalian aerobic glucose fermentation metabolic pathway, then general metabolic processes can be monitored, but specific detection of mam-aGF is not achievable due to lack of specific markers
Solution Approach 1:
The patent introduces TKTL1 as an intermediary marker that specifically mediates the detection of mam-aGF. TKTL1 serves as a bridge between the metabolic pathway and detection methods, enabling specific identification of mam-aGF through its unique expression pattern and enzymatic function in aerobic glucose fermentation.
Solution Approach 2:
The patent utilizes changes in TKTL1 expression levels and enzymatic activity as detectable parameters to indicate mam-aGF status. By monitoring TKTL1 mRNA expression, protein levels, and transketolase activity, the method transforms the invisible metabolic pathway into measurable parameters that can be detected and quantified.
2Measurement precision
If TKTL1 is used as a specific marker for mam-aGF detection, then detection precision is improved, but the complexity of detection methods increases due to multiple assessment parameters
Solution Approach 1:
The patent divides the detection process into distinct segments: mRNA expression analysis, protein level detection, and enzymatic activity measurement. Each segment can be performed using separate, well-established techniques, allowing the complex detection task to be broken down into manageable, modular components that can be executed independently.
Solution Approach 2:
The patent employs universal detection techniques that can assess multiple parameters of TKTL1 using standard molecular biology methods. The same general approach (mRNA analysis, protein detection, activity measurement) can be applied to various biological samples and contexts, reducing the need for specialized equipment while maintaining detection precision.
3Reliability
If TKTL1 activity is modulated for therapeutic purposes, then disease treatment effectiveness is improved, but the risk of off-target effects increases due to TKTL1's physiological functions
Solution Approach 1:
The patent employs local quality control by targeting TKTL1 modulation specifically in pathological contexts where mam-aGF is aberrantly activated. By using TKTL1 as a biomarker to identify affected tissues or cells, therapeutic interventions can be localized to areas where the metabolic pathway is dysregulated, minimizing impact on normal physiological functions in healthy tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables early detection and monitoring of mam-aGF-related diseases, allowing for tailored therapy strategies and potentially inhibiting tumor growth or preventing neurodegenerative conditions by modulating TKTL1 enzyme activity.
Implementation Method 1
employing monoclonal antibodies and nucleic acid probes to assess its activity, concentration, localization, and dimerization status
Implementation Method 2
employing monoclonal antibodies and nucleic acid probes to assess its activity, concentration, localization, and dimerization status
Implementation Method 3
the enzyme TKTL1 is the tracer enzyme of said new glucose fermentation metabolism
Implementation Method 4
a metabolism pathway which up to now has been known only from prokaryotic cells (for example from lactobacillus), exists in mammalian organisms—i.e. in mammalian cells—too, said metabolism pathway comprising the energy-yielding breaking down of glucose to lactate
Data Source
AI summary
The method for qualitative and qualitative detecting of the extend of use and the correct process flow of the mammalian aerobic glucose fermentation metabolic pathway (mam-aGF) in a mammalian individual is characterized in that the enzyme TKTL1 is used as indicator and target molecule and the structural and/or functional parameter of said TKTL1 in a biological sample of said individual (patient) are taken as indication for the qualitative and qualitative run of the mam-aGF in the cells and/or tissue of said individual (patient). In combination with the use of inhibitors and activators of the mam-aGF the method is further suitable for checking and controlling the mam-aGF in an individual (patient).